Onyx Biotec (NSE:ONYX) Research & Development: ₹0.0 Mil (TTM As of Mar. 2026)


NSE:ONYX Onyx Biotec Ltd NSE:ONYX
13 GF Score
Price ₹38.95
! 6 Warning Signs
View Full Analysis

What is Onyx Biotec Research & Development?

Onyx Biotec NSE:ONYX 13 Research & Development is ₹0.0 Mil as of Mar. 2026. GuruFocus rates NSE:ONYX with a GF Score™ of 13/100. The stock has 6 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Onyx Biotec's Research & Development for the six months ended in Mar. 2026 was ₹0.0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was ₹0.0 Mil.

Onyx Biotec  (NSE:ONYX) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Onyx Biotec Research & Development Related Terms

Onyx Biotec Research & Development Historical Data

* Premium members only.

The historical data trend for Onyx Biotec's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Onyx Biotec Research & Development Chart

Onyx Biotec Annual Data
Trend Mar22 Mar23 Mar24 Mar25 Mar26
Research & Development
0.00 0.00 0.00 0.00 0.00

Onyx Biotec Semi-Annual Data
Mar22 Mar23 Mar24 Sep24 Mar25 Sep25 Mar26
Research & Development Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00
NSE:ONYX
13GF Score
Onyx Biotec Ltd NSE:ONYX
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Onyx Biotec Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was ₹0.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of ₹0.0 Mil mean?
Onyx Biotec (NSE:ONYX) has a Research & Development of ₹0.0 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Onyx Biotec and its competitors.
Is Onyx Biotec's Research & Development too high?
Onyx Biotec's current Research & Development is ₹0.0 Mil. Overall, Onyx Biotec has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does Onyx Biotec's Research & Development compare to ISRG and BDX?
Onyx Biotec's Research & Development of ₹0.0 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Medical Devices & Instruments company?
A good Research & Development depends on the Medical Devices & Instruments industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Onyx Biotec and its competitors. Onyx Biotec's current Research & Development is ₹0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Onyx Biotec stock overvalued right now?
Onyx Biotec (NSE:ONYX) has a current Research & Development of ₹0.0 Mil. The current Research & Development is ₹0.0 Mil. Onyx Biotec's overall GF Score™ is 13/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Onyx Biotec (NSE:ONYX), the current Research & Development is ₹0.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Onyx Biotec Business Description

Address Nalagarh Road, Near Sainimajraropar, Village Bir Plassi, Solan, HP, IND, 174101
Onyx Biotec Ltd is engaged in healthcare segment and offering Sterile Pharmaceutical products ,and acts as a pharmaceutical contract manufacturer. It offering products such as Sterile Water for Injections, Dry Powder Injections and Dry Syrup for India and overseas. Key revenue is generated from Sterile Water for Injections .
13GF Score

Get the complete analysis for NSE:ONYX

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹38.95
Price